Transparency Market Research

Recombinantly Made Drugs Most Preferred in Global Gaucher Disease Drugs Market

Transparency Market Research Report Added "Gaucher Disease Drugs Market" to its database.


Albany, NY -- (SBWIRE) -- 12/07/2016 -- The global market for gaucher disease drugs is examined in a recent market research report by Transparency Market Research. The detailed report, assessing the various segments, driving and restraining factors, trends, and key growth opportunities is titled "Gaucher Disease Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013–2019."

The report presents a thorough overview of the current state of the gaucher disease drugs market and examines the several developments that are expected to affect the future growth prospects of the market over the period between 2013 and 2019. As such, a detailed overview of key pipeline drugs, strategic collaborations such as mergers and acquisitions, and the introduction of new products in the market are examined at great depths.

Read Full Report:

The report provides a thorough perspective of the market and its current situation with the help of analysis techniques such as Porter's five forces model and SWOT analysis. The detailed data about several key elements of the market allows the reader a clear understanding of the growth areas, state of competitive rivalry, and scope of innovation.

The key factor driving the global gaucher disease drugs market is the rising demand for a substantial and economical course of treatment for the disease. Presently, the disease is treated with the help of enzyme replacement therapy. Enzyme replacement therapy is heavily expensive and requires treatment throughout the lifetime of a patient. However, owing to the rarity of the disease, the healthcare practitioners have encountered challenges in finding the optimal dosage and dosing frequency of intravenous recombinant glucocerebrosidase.

To avoid the high cost that this course of treatment invariably carries, the efforts towards the development of gaucher treatment drugs have gathered pace. The low incidence of the disease on a global front, with most cases concentrated in Eastern Europe, gaucher drugs have gained the title of orphan drug across several countries. As a result, development in the gaucher disease drugs market is largely dependent on recognition and funding from government bodies to support research into medicines that address a small population base.

Download exclusive Sample of this Report:

One of the key trends in the market is the development of drugs with the help of recombinant DNA technology. One of the first gaucher drugs, alglucerase (Ceredase), was made from glucocerebrosidase gathered from human placental tissue and then modified with the help of enzymes. The drug has been withdrawn from the market owing to the approval of similar drugs made with the help of recombinant DNA technology.

The report presents a thorough overview of the competitive landscape of the global gaucher disease drugs market with the help of detailed business profiles of some of the key companies operating in the market. The companies operating in the market profiled in the report are JCR Pharmaceuticals, Genzyme Corporation, Protalix BioTherapeutics, Neuraltus Pharmaceuticals, ExSAR Corporation, Dong-A-Socio Holdings, Amicus Therapeutics, Greenovation Biotech GmbH, and Lixte Biotechnology Holdings.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453